BIOCON, Author at Biocon

Leaving the Biocon site!

You are now leaving the Biocon website for a Biocon affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Mylan and Biocon Receive Approvals from the European Commission and TGA, Australia for Semglee™ Biosimilar Insulin Glargine

Update on Company Statement on US-FDA Inspection at Biocon Malaysia

Company Statement on US-FDA Inspection at Biocon Malaysia

Mylan and Biocon Receive Positive CHMP Opinion for Semglee™, Biosimilar Insulin Glargine

Biocon Q3FY18 Revenue at Rs 1092 Crore; EBITDA at Rs 256 Crore; Net Profit at Rs 92 Crore

Biocon Announces Exclusive Global Collaboration with Sandoz on Next-Generation Biosimilars

Biocon and Mylan’s Biosimilar Trastuzumab Receives Approval from ANVISA, Brazil Through Their Partner Libbs

Biocon´s Clarification post media reports on “Biocon on the FDA list for not paying facility fee”

U.S. FDA Approves Mylan and Biocon´s OgivriTM the First Biosimilar for Trastuzumab, for the Treatment of HER2Positive Breast and Gastric Cancers

European Medicines Agency Accepts Marketing Authorization Applications for Mylan and Biocon´s Proposed Biosimilars Trastuzumab and Pegfilgrastim